Phase I Trial of Uracil–Ftorafur, Leucovorin, and Etoposide: An Active All-oral Regimen for Metastatic Breast Cancer
Authors:
- 1 November 2003
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 82 (1) , 61-69
Abstract
Purpose. To determine the maximum tolerated doses, toxicities, and therapeutic effect of an oral chemotherapy regimen consisting of uracil–ftorafur, etoposide, and leucovorin for metastatic breast cancer. Patients and methods. The regimen consists of 28-day cycles of uracil–ftorafur, etoposide, and leucovorin administered orally on days 1–14. The dose of etoposide was fixed at 50 mg/m2/day, and uracil–ftorafur was escalated in 50 mg/m2/day increments from 200 to 350 mg/m2. Leucovorin, was used at a dose of 90 mg/day. Eligibility criteria required prior treatment with a taxane or anthracycline. Results. A total of 23 patients were enrolled. Twenty patients are assessable for toxicity and 16 patients are assessable for response. All non-hematologic toxicities were grade 1 or 2. Three hematologic dose-limiting toxicities (DLTs) were observed. Partial responses were seen in 6 of 16 (37.5%, 95% confidence interval 15%, 85%) of assessable patients with durations ranging from 4 to 20 months. Stable disease was observed in 4 of 16 (25%) of patients with durations from 4 to 12 months. Median time to progression was 10.5 months. An intent to treat analysis revealed a response of 26%. Conclusion. The recommended dose and schedule of this combination is uracil–ftorafur 350 mg/m2, leucovorin 90 mg/day, and etoposide 50 mg/m2 for two consecutive weeks in a 4-week cycle. This all-oral regimen is well tolerated and demonstrates encouraging efficacy in a cohort of heavily pretreated patient with metastatic breast cancer.Keywords
This publication has 24 references indexed in Scilit:
- Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial ResultsJournal of Clinical Oncology, 2002
- Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxicAnnals of Oncology, 1996
- Daily oral etoposide in metastatic breast cancerAnti-Cancer Drugs, 1996
- Protracted Continuous Infusion of 5-Fluorouracil in Combination with Doxorubicin, Vincristine, and Oral Cyclophospharnide in Advanced Breast CancerCancer Investigation, 1996
- Oral tegafur in the treatment of metastatic breast cancer: A phase II studyEuropean Journal of Cancer, 1993
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast CancerJNCI: Journal of the National Cancer Institute, 1991
- 5-Fluorouracil by Protracted Venous Infusion: A Review of Recent Clinical StudiesCancer Investigation, 1991
- Taxol: A Novel Investigational Antimicrotubule AgentJNCI: Journal of the National Cancer Institute, 1990
- Metabolic activation of ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathwayBiochemical Pharmacology, 1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958